Gennari C, Agnusdei D, Camporeale A
Institute of Internal Medicine and Medical Pathology, University of Siena, Italy.
Horm Metab Res. 1993 Sep;25(9):484-5. doi: 10.1055/s-2007-1002155.
Many studies have shown that calcitonin has beneficial effects on the clinical and biological disturbances of diseases characterized by an excessive bone remodelling. Several controlled clinical studies have shown that long-term calcitonin treatment, given by parenteral or intranasal routes, exerts a beneficial positive effect on bone mass and bone turnover in established postmenopausal osteoporosis. Calcitonin therapy is particularly indicated for patients with high turnover osteoporosis where results show a net gain of bone mineral in the axial skeleton and a slowing of bone loss in the appendicular bones. Recently, calcitonin was shown to induce a significant reduction in postmenopausal osteoporotic vertebral fractures. Due to receptor down-regulation a resistance to the hormone may occur after 12-18 months of continuous treatment. Reported results of long-term calcitonin treatment demonstrated that it is possible to delay or to avoid the "resistance" to calcitonin by the cyclical or discontinued administration of the hormone.
许多研究表明，降钙素对以骨重塑过度为特征的疾病的临床和生物学紊乱具有有益作用。多项对照临床研究表明，通过胃肠外或鼻内途径给予的长期降钙素治疗，对已确诊的绝经后骨质疏松症的骨量和骨转换具有有益的积极作用。降钙素疗法特别适用于高转换型骨质疏松症患者，其结果显示轴向骨骼的骨矿物质净增加，附属骨骼的骨质流失减缓。最近，降钙素被证明可显著降低绝经后骨质疏松性椎体骨折的发生率。由于受体下调，连续治疗12 - 18个月后可能会出现对该激素的抵抗。长期降钙素治疗的报告结果表明，通过周期性或间断给药该激素，有可能延迟或避免对降钙素的“抵抗”。
